{"id":"brand-name-latanoprost","safety":{"commonSideEffects":[{"rate":null,"effect":"Increased iris pigmentation"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Eyelash growth (hypertrichosis)"},{"rate":null,"effect":"Eye irritation or discomfort"},{"rate":null,"effect":"Periocular skin darkening"}]},"_chembl":{"chemblId":"CHEMBL1051","moleculeType":"Small molecule","molecularWeight":"432.60"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Latanoprost acts as a selective agonist at the FP prostaglandin receptor in the eye. By activating this receptor, it enhances drainage of aqueous humor through the uveoscleral (unconventional) pathway, which is the primary mechanism for reducing intraocular pressure. This reduction in IOP helps prevent or slow progression of glaucomatous damage.","oneSentence":"Latanoprost is a prostaglandin F analog that binds to the prostaglandin F (FP) receptor to increase uveoscleral outflow of aqueous humor, thereby lowering intraocular pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:22:09.680Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT02047630","phase":"PHASE4","title":"Efficacy of the Brand-name Latanoprost and One of Its Generic Version in Primary Open Angle Glaucoma and Ocular Hypertension","status":"TERMINATED","sponsor":"CHU de Quebec-Universite Laval","startDate":"2014-01","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Xalatan"],"phase":"marketed","status":"active","brandName":"Brand-name latanoprost","genericName":"Brand-name latanoprost","companyName":"CHU de Quebec-Universite Laval","companyId":"chu-de-quebec-universite-laval","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Latanoprost is a prostaglandin F analog that binds to the prostaglandin F (FP) receptor to increase uveoscleral outflow of aqueous humor, thereby lowering intraocular pressure. Used for Open-angle glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}